Pulmonary pleomorphic carcinoma treated with PD‐1 inhibitor: Two case reports

Pulmonary polymorphic carcinoma (PPC) is a rare and poorly differentiated form of non‐small cell lung cancer (NSCLC), accounting for just approximately 0.1% to 0.4% of all NSCLC cases. Historically, the conventional treatments for PPC have been linked to a grim prognosis. However, with the advent of...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Tao, Wang, Hao, Xue, Fei, Wu, Xuanpeng, Ni, Ming, Wang, Yuanyuan, Chen, Nanzheng, Zhang, Yong, Zhang, Guangjian, Fu, Junke, Liu, Xi, Wu, Qifei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643791/
https://www.ncbi.nlm.nih.gov/pubmed/37779217
http://dx.doi.org/10.1111/1759-7714.15120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643791/
https://www.ncbi.nlm.nih.gov/pubmed/37779217
http://dx.doi.org/10.1111/1759-7714.15120

Ejemplares similares